• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TFS International acquires Beardsworth Consulting

TFS International acquires Beardsworth Consulting

May 6, 2013
CenterWatch Staff

In a move to expand its oncology and vaccine research services, TFS International, a full service CRO, has completed the acquisition of Beardsworth Consulting Group (BCG), a New Jersey-based oncology and vaccine specialist CRO.

The acquisition of BCG follows the TFS global strategy to grow its North American operations to 600 professionals with comparable capabilities and expertise to its existing European business. The BCG acquisition will complement TFS' competences in oncology and vaccines, among several others therapeutics areas, as well as provide scalable operational resources throughout North America. BCG's operations include comprehensive clinical research services together with project management and monitoring across all study phases, data management, biostatistics, regulatory consulting and medical writing.

"The BCG deal is really a welcomed component in the strategic vision of TFS,” said Daniel Spasic, CEO of TFS “It adds competencies in active and growing therapeutic areas, increases our operational capabilities in North America and expands substantially our customer portfolio of smaller and midsized life science companies in one of the most important global research markets. It aligns very well with where we want to be as a company.”

The BCG deal follows two other TFS acquisitions in the last five months, including the acquisition of Dimensione Ricerca in Italy and the technology provider for electronic data capture (EDC) services, Semcon in Sweden. 

"We are very pleased to have found a global partner through the TFS Group,” said Doug Beardsworth, executive chairman at BCG. “TFS and BCG share a common culture of quality and professional service of the highest caliber.  As a combined operation, we now have significant resources deployed across multiple continents. It is rewarding to know that our global capabilities will now provide considerable value to our clients, and the patients that we ultimately serve.”

TFS and BCG have had a history of collaboration on several global clinical programs in oncology and other therapeutic areas. Operational processes and quality systems are well established, which will facilitate an efficient integration between the two groups as well as ensuring business continuity and focus on the ongoing clinical projects and customers.

"Hani Zaki will be taking the helm for the TFS U.S. organization as the executive vice president and president, Americas,” said Spasic. “He is a seasoned and trusted pharmaceutical and CRO executive who has spent many years working for public and private CROs, and is a well-respected professional within the life science community.”

The terms and conditions of the acquisition have not been disclosed.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing